Millipore Sigma Vibrant Logo

OP93 Anti-BRCA1 (Ab-2) Mouse mAb (MS13)

Anti-BRCA1 (Ab-2), mouse monoclonal, clone MS13, recognizes ~220 kDa BRCA1 in MCF-7 cells. It is validated for Western blotting, immunofluorescence, immunoprecipitation, and for paraffin sections.

Anti-BRCA1 (Ab-2) Mouse mAb (MS13): SDB (Sicherheitsdatenblätter), Analysenzertifikate und Qualitätszertifikate, Dossiers, Broschüren und andere verfügbare Dokumente.

Synonyme: Anti-Breast Cancer Susceptibility Protein

View Products on Sigmaaldrich.com
OP93
Preis & Verfügbarkeit

Übersicht

Replacement Information

Key Spec Table

Species ReactivityHostAntibody Type
HMMonoclonal Antibody

Preis & Verfügbarkeit

Bestellnummer VerfügbarkeitVerpackung St./Pkg. Preis Menge
OP93-100UG
Verfügbarkeit wird abgerufen...
—
Eingeschränkte Verfügbarkeit Eingeschränkte Verfügbarkeit
Lieferbar 
Produkt wurde eingestellt
Begrenzter Lagerbestand
Bestätigung der Verfügbarkeit erforderlich
    Restmenge: Angebot folgt
      Restmenge: Angebot folgt
      Bitte erfragen
      Kontakt zum Kundenservice
      Contact Customer Service

      		 Kst.-Ampulle 100 μg
      Preis wird abgerufen...
      Preis nicht abrufbar
      Die Mindestmenge muss ein Vielfaches sein von
      Maximum Quantity is
      Bei Bestätigung Weitere Informationen
      Sie haben () gespart
       
      —
      Bitte erfragen
      		 —
      Description
      OverviewRecognizes the ~220 kDa BRCA1 protein in MCF-7 cells. Does not react with blood group antigens or growth factor receptors such as EGFR. Sold under license of U.S. Patent 5,753,441 and 6,162,897.
      Catalogue NumberOP93
      Brand Family Calbiochem®
      SynonymsAnti-Breast Cancer Susceptibility Protein
      References
      ReferencesScully, R., et al. 1996. Science 272, 123.
      Gudas, J.M., et al. 1996. Cell Growth Differ. 7, 717.
      Vaughn, J.P., et al. 1996. Cell Growth Differ. 7, 711.
      Goldgar, D.E. and Reilly, P.R. 1995. Nat. Genet. 11, 113.
      Merajver, S.D., et al. 1995. Clin. Can. Res. 1, 539.
      Merajver, S.D., et al. 1995. Nat. Genet. 9, 439.
      Struewing, J.P., et al. 1995. Nat. Genet. 11, 198.
      Thompson, M.E., et al. 1995. Nat. Genet. 9, 444.
      Futreal, P.A., et al. 1994. Science 266, 120.
      Miki, Y., et al. 1994. Science 266, 66.
      Product Information
      DeclarationSold under license of U.S. Patents 5,753,441 and 6,162,897.
      FormLiquid
      FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
      Positive controlMCF7 cells
      Preservative≤0.1% sodium azide
      Quality LevelMQ100
      Applications
      Application ReferencesImmunoblotting, Immunoprecipitation, Immunofluorescence, Paraffin Sections Scully, R., et al. 1996. Science 272, 123.
      Key Applications Immunoblotting (Western Blotting)
      Immunofluorescence
      Immunoprecipitation
      Paraffin Sections
      Application NotesImmunoblotting (2 µg/ml, chemiluminescence; see application references)
      Immunofluorescence (see application references)
      Immunoprecipitation (see application references)
      Paraffin Sections (see application references)
      Application CommentsAntibody should be titrated for optimal results in individual systems.
      Biological Information
      Immunogenrecombinant, human BRCA1
      ImmunogenHuman
      Epitopewithin amino acids 1-304
      CloneMS13
      HostMouse
      IsotypeIgG₁
      Species Reactivity
      • Human
      Antibody TypeMonoclonal Antibody
      Concentration Label Please refer to vial label for lot-specific concentration
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Blue Ice Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Do not freeze Yes
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Bestellnummer GTIN
      OP93-100UG 04055977209693

      Documentation

      Anti-BRCA1 (Ab-2) Mouse mAb (MS13) SDB

      Titel

      Sicherheitsdatenblatt (SDB) 

      Anti-BRCA1 (Ab-2) Mouse mAb (MS13) Analysenzertifikate

      TitelChargennummer
      OP93

      Literatur

      Übersicht
      Scully, R., et al. 1996. Science 272, 123.
      Gudas, J.M., et al. 1996. Cell Growth Differ. 7, 717.
      Vaughn, J.P., et al. 1996. Cell Growth Differ. 7, 711.
      Goldgar, D.E. and Reilly, P.R. 1995. Nat. Genet. 11, 113.
      Merajver, S.D., et al. 1995. Clin. Can. Res. 1, 539.
      Merajver, S.D., et al. 1995. Nat. Genet. 9, 439.
      Struewing, J.P., et al. 1995. Nat. Genet. 11, 198.
      Thompson, M.E., et al. 1995. Nat. Genet. 9, 444.
      Futreal, P.A., et al. 1994. Science 266, 120.
      Miki, Y., et al. 1994. Science 266, 66.
      Datenblatt

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision03-October-2007 RFH
      SynonymsAnti-Breast Cancer Susceptibility Protein
      ApplicationImmunoblotting (2 µg/ml, chemiluminescence; see application references)
      Immunofluorescence (see application references)
      Immunoprecipitation (see application references)
      Paraffin Sections (see application references)
      DescriptionPurified mouse monoclonal antibody generated by immunizing mice with the specified iummunogen and fusing splenocytes with NS1 mouse myeloma cells. Recognizes the ~220 kDa BRCA1 protein.
      BackgroundInactivation of the BRCA1 gene, located at 17q21, is responsible for some forms of familial breast and ovarian cancer and sporadic ovarian cancer. BRCA1 encodes a protein of 1863 amino acids with an amino-terminal domain that exhibits similarity to the zinc-ring domain found in several regulatory and transcription factors. Mutations that disrupt this domain are some of the most frequently occurring ones linked to breast and ovarian cancer. Inhibition of BRCA1 expression leads to accelerated growth of mammary cells in vitro while loss of expression is observed during progression from benign disease to metastatic breast cancer suggesting that BRCA1 serves as a negative growth regulator. The ~220 kDa BRCA1 protein is expressed predominantly in the nucleus and appears to undergo cell cycle regulation with mRNA expression induced prior to DNA synthesis.
      HostMouse
      Immunogen speciesHuman
      Immunogenrecombinant, human BRCA1
      Epitopewithin amino acids 1-304
      CloneMS13
      IsotypeIgG₁
      Specieshuman
      Positive controlMCF7 cells
      FormLiquid
      FormulationIn 0.05 M sodium phosphate buffer, 0.2% gelatin.
      Concentration Label Please refer to vial label for lot-specific concentration
      Preservative≤0.1% sodium azide
      CommentsAntibody should be titrated for optimal results in individual systems.
      Storage +2°C to +8°C
      Do Not Freeze Yes
      Toxicity Standard Handling
      ReferencesScully, R., et al. 1996. Science 272, 123.
      Gudas, J.M., et al. 1996. Cell Growth Differ. 7, 717.
      Vaughn, J.P., et al. 1996. Cell Growth Differ. 7, 711.
      Goldgar, D.E. and Reilly, P.R. 1995. Nat. Genet. 11, 113.
      Merajver, S.D., et al. 1995. Clin. Can. Res. 1, 539.
      Merajver, S.D., et al. 1995. Nat. Genet. 9, 439.
      Struewing, J.P., et al. 1995. Nat. Genet. 11, 198.
      Thompson, M.E., et al. 1995. Nat. Genet. 9, 444.
      Futreal, P.A., et al. 1994. Science 266, 120.
      Miki, Y., et al. 1994. Science 266, 66.
      Application referencesImmunoblotting, Immunoprecipitation, Immunofluorescence, Paraffin Sections Scully, R., et al. 1996. Science 272, 123.